Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
With the firm seeing lower profitability in diagnostics, its CEO said it is focusing on improving earnings strength with the Atellica Solution IVD platform.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business.
LabCorp Diagnostics was down 2.8 percent, while Covance Drug Development was up 8 percent. The firm narrowed its revenue and earnings guidance for the year.
Qiagen reported year-over-year net sales of 1 percent, or 5 percent at constant exchange rates ahead of its planned Q2 earnings release next week.
The firm had revenues of $6.32 billion in Q2, up 4 percent from $6.08 billion last year and just beating the average Wall Street estimate of $6.3 billion.
The lab beat the consensus Wall Street estimate on the top and bottom line, and maintained its revenue and adjusted EPS guidance for full-year 2019.
The revenue increase was driven by increased sales across all of the French diagnostic and theranostics firm's business segments.